
Ada is a global health company founded by doctors, aiming to improve health outcomes through intelligent technology. Their core product is a personal health companion app, often referred to as a symptom checker, which utilizes AI and clinical evidence to help users understand their symptoms, manage their health, and find appropriate care. The app is highly rated and has a significant user base, indicated by metrics such as 14 million users and 35 million symptom assessments completed. Ada also offers enterprise solutions for healthcare systems, insurers, life sciences, and employers, helping them with health decision-making, care triage, and cost reduction. The company emphasizes accuracy, confidentiality, and trustworthiness, with their technology being recognized and adopted globally.

Ada is a global health company founded by doctors, aiming to improve health outcomes through intelligent technology. Their core product is a personal health companion app, often referred to as a symptom checker, which utilizes AI and clinical evidence to help users understand their symptoms, manage their health, and find appropriate care. The app is highly rated and has a significant user base, indicated by metrics such as 14 million users and 35 million symptom assessments completed. Ada also offers enterprise solutions for healthcare systems, insurers, life sciences, and employers, helping them with health decision-making, care triage, and cost reduction. The company emphasizes accuracy, confidentiality, and trustworthiness, with their technology being recognized and adopted globally.
What they do: AI-powered symptom assessment and care navigation (consumer app + enterprise solutions)
Founded: 2011
Headcount (approx.): 224
Funding to date: USD 189,500,000 (multiple rounds; Series B extended)
Regulatory: Ada Assess certified as EU-MDR Class IIa medical device (Dec 15, 2022)
Symptom assessment, care navigation, clinical decision support for consumers and healthcare organizations.
2011
Digital health / Healthtech
47000000.00
90000000.00
30000000.00
Extension increased Series B total to $120M; new participants included Farallon Capital and Bertelsmann Investments
“Includes strategic and institutional investors such as Leaps by Bayer, Access Industries, Farallon Capital, and Bertelsmann Investments”